Seroflo 250 InhalerFitness Gear & Equipment
Seroflo 250 inhaler
Seroflo 250 inhaler is a medication with active ingredients salmeterol xinafoate and fluticasone propionate administered in the treatment of asthma and constant obtrusive pulmonary syndrome.
Fluticasone, from the corticosteroid group, is the anti inflammatory constituent of the medication, while salmeterol takes care of restriction of the airways. Mutually, they alleviate the indications of wheezing, coughing, and difficulty in breathing superior than whichever salmeterol or fluticasone or used individually.
Salmeterol, an extended performing beta-two agonist which operates in the vicinity in the lung to intercede bronchodilation. Fluticasone, a corticosteroid with primarily glucocorticoid action, decrease indications and exacerbations of asthma.
Bronchodilation: 10 to 20 mins.
Bronchodilation: 12 hrs
Salmeterol: insignificant assimilation after breathing. Fluticasone: inadequately immersed from the GI tract; oral bioavailability less than 1 percent; complete bioavailability of inhaled fluticasone: 5 to 11 percent.
Protein binding for Salmeterol 96 percent.
Protein binding for Fluticasone 91percent.
Salmeterol: Discharged largely in feces; insignificant quantity of unaffected salmeterol are measurable in urine or feces. Fluticasone: chiefly discharged in feces as metabolites and unaffected dmedication; less than 5 percent discharged in urine.
seroflo 250 Side Effects
throat and Mouth candidiasis, dysphonia/ hoarseness, throat irritation, lower respiratory tract infections , nasopharyngitis, headache, hypokalaemia, tremors, muscle cramps, palpitation. Protracted high dosage may root Cushingoid features, Cushing's syndrome, bone mineral concentration decline,adrenal suppression, slow down of development in children and teenagers, glaucoma and cataract.
Potentially Fatal: Paradoxical broncho-spasm.
Salmeterol may amplify the danger of asthma associated casualty. As a result, recommend salmeterol or salmeterol containing drugs only for subjects not sufficiently prohibited on other asthma regulator drugs or whose ailment sternness evidently necessitates commencement of therapy with seroflo 250 inhalers (salmeterol and fluticasone products).
acutee cardiovascular problems, Pulmonary TB, irregular heartbeats, heart rhythm abnormalities, thyrotoxicosis, DM, hypokalaemia. Subjects at danger of reduced bone mineral density (e.g. old age, smoking, sedentary lifestyle, family history of osteoporosis, poor nutrition or long term administration of medications that may reduce bone mass (e.g. anticonvulsants and corticosteroids). Do not discontinue treatment suddenly; treatment ought to be down titrated. Recommend subject to clean mouth after inhalation. observe tallness of children on extended treatment. Pregnancy as well as lactation.